Cardiovascular Outcomes with Ertugliflozin in Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The cardiovascular effects of ertugliflozin, an inhibitor of sodium-glucose cotransporter 2, have not been established. METHODS: In a multicenter, double-blind trial, we randomly assigned patients with type 2 diabetes and atherosclerotic cardiovascular disease to receive 5 mg or 15 mg of ertugliflozin or placebo once daily. With the data from the two ertugliflozin dose groups pooled for analysis, the primary objective was to show the noninferiority of ertugliflozin to placebo with respect to the primary outcome, major adverse cardiovascular events (a composite of death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke). The noninferiority margin was 1.3 (upper boundary of a 95.6% confidence interval for the hazard ratio [ertugliflozin vs. placebo] for major adverse cardiovascular events). The first key secondary outcome was a composite of death from cardiovascular causes or hospitalization for heart failure. RESULTS: A total of 8246 patients underwent randomization and were followed for a mean of 3.5 years. Among 8238 patients who received at least one dose of ertugliflozin or placebo, a major adverse cardiovascular event occurred in 653 of 5493 patients (11.9%) in the ertugliflozin group and in 327 of 2745 patients (11.9%) in the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noninferiority). Death from cardiovascular causes or hospitalization for heart failure occurred in 444 of 5499 patients (8.1%) in the ertugliflozin group and in 250 of 2747 patients (9.1%) in the placebo group (hazard ratio, 0.88; 95.8% CI, 0.75 to 1.03; P = 0.11 for superiority). The hazard ratio for death from cardiovascular causes was 0.92 (95.8% CI, 0.77 to 1.11), and the hazard ratio for death from renal causes, renal replacement therapy, or doubling of the serum creatinine level was 0.81 (95.8% CI, 0.63 to 1.04). Amputations were performed in 54 patients (2.0%) who received the 5-mg dose of ertugliflozin and in 57 patients (2.1%) who received the 15-mg dose, as compared with 45 patients (1.6%) who received placebo. CONCLUSIONS: Among patients with type 2 diabetes and atherosclerotic cardiovascular disease, ertugliflozin was noninferior to placebo with respect to major adverse cardiovascular events. (Funded by Merck Sharp & Dohme and Pfizer; VERTIS CV ClinicalTrials.gov number, NCT01986881.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The trial of once-weekly exenatide demonstrated a directionally favorable effect on MACE but narrowly missed statistical significance.644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“In the CVOTs Harmony Outcomes (albiglutide vs placebo), EXSCEL (exenatide LA vs placebo), and AMPLITUDE-O (efpeglenatide vs placebo), there were numerically fewer strokes, but HRs were not significant.472,641,644”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [644]
In the citing paper
“The SGLT2i cardiovascular outcome trials (CVOTs) have reported DKA rates of 0.1 -0.6% compared with rates of < 0.1 -0.3% with placebo (143 -147), with very low rates in the HF (148 -151) and CKD (152,153) outcome studies.”
In the citing paper
“In the Evaluation of Ertugli fl ozin Ef fi cacy and Safety CVOT (VERTIS CV), which recruited exclusively people with established CVD and type 2 diabetes, ertugli fl ozin was similar to placebo with respect to the primary MACE outcome and all key secondary outcomes (including a composite kidney outcome) except for HHF (146).”
In the citing paper
“While there was a trend for bene fi t for the key secondary endpoint of cardiovascular death or heart failure hospitalization, this did not meet statistical signi fi cance (HR: 0.88; 95% CI: 0.75 -1.03).”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [91]
18 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812389 · Cited by 6,382
Self-citationCanagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Self-citationEmpagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Mortality and cardiovascular disease in type 1 and type 2 diabetes
Rawshani, A., Rawshani, A., Franzén, S., Eliasson, B., Svensson, A.-M., Miftaraj, M., McGuire, D. K., Sattar, N., Rosengren, A., & Gudbjörnsdottir, S. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1608664 · Cited by 1,389
Self-citationKDOQI clinical practice guideline for diabetes and CKD: 2012 update
(2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.07.005 · Cited by 1,320
Changing epidemiology of type 2 diabetes mellitus and associated chronic kidney disease
Thomas, M. C., Cooper, M. E., & Zimmet, P. (2016) · Nature Reviews Nephrology · doi:10.1038/nrneph.2015.173 · Cited by 742
Interim analysis: The alpha spending function approach
Demets, D. L., & Lan, K. K. G. (1994) · Statistics in Medicine · doi:10.1002/sim.4780131308 · Cited by 564
Cannon, C. P., McGuire, D. K., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Charbonnel, B., Shih, W. J., Gallo, S., Masiukiewicz, U., et al. (2018) · American Heart Journal · doi:10.1016/j.ahj.2018.08.016 · Cited by 203
Self-citation
Research works printed but not linked: 1
- Food and Drug Administration. Guidance for industry: diabetes mellitus — evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes. Fed Regist 2008;73(245):77724-77725 (https://www.govinfo.gov/content/pkg/FR-2008-12-19/pdf/E8-30086.pdf).
Cited by
Items 401–500 of 1,001
Yankah, R. K., Anku, E. K., & Eligar, V. S. (2024) · Journal of Diabetes Research · doi:10.1155/2024/9985836 · Cited by 24
Novel Cardiometabolic Medications in the Cardiovascular-Kidney-Metabolic Syndrome Era
Pohlman, N., Patel, P. N., Essien, U. R., Tang, J., & Joseph, J. J. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf295 · Cited by 28
Yoosuf, B. T., Muhammed Favas, K. T., Spoorthy, D. P., Saini, A., Garg, P., Medenica, S., Dutta, P. R., & Bansal, D. (2025) · Endocrine · doi:10.1007/s12020-025-04393-7 · Cited by 24
Ertugliflozin in the treatment of type 2 diabetes mellitus
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-7-4 · Cited by 31
Teo, Y. H., Yoong, C. S. Y., Syn, N. L. X., Teo, Y. N., Cheong, J. Y. A., Lim, Y. C., Lee, C., Yeo, T., Chai, P., Wong, R. C.-C., et al. (2021) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-021-03147-4 · Cited by 23
“However, the recently published VERTIS CV trial (Evaluation of Ertugliflozin Efficacy and Safety Cardiovascular Outcomes Trial) [14] that examined the use of Ertugliflozin in diabetic patients with the atherosclerotic disease showed relatively inferior treatment effects compared to other SGLT2 inhibitors.”
ResultRau, M., Thiele, K., Hartmann, N. K., Möllmann, J., Wied, S., Böhm, M., Scharnagl, H., März, W., Marx, N., & Lehrke, M. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.06.915 · Cited by 24
Chun, K. J., & Jung, H. H. (2021) · Kidney Medicine · doi:10.1016/j.xkme.2021.04.009 · Cited by 29
See, R. M., Teo, Y. N., Teo, Y. H., Syn, N. L. X., Yip, A. S. Y., Leong, S., Wee, C. F., Cheong, A. J. Y., Lee, C., Chan, M. Y., et al. (2021) · Pharmacology · doi:10.1159/000520903 · Cited by 27
New Hypoglycemic Drugs: Combination Drugs and Targets Discovery
Ni, X., Zhang, L., Feng, X., & Tang, L. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.877797 · Cited by 26
Nusca, A., Piccirillo, F., Viscusi, M. M., Giannone, S., Mangiacapra, F., Melfi, R., Ricottini, E., Ussia, G. P., & Grigioni, F. (2022) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001329 · Cited by 25
Maddaloni, E., Cavallari, I., Porta, Y. L., Appetecchia, A., D’Onofrio, L., Grigioni, F., Buzzetti, R., & Holman, R. R. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14986 · Cited by 28
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C., Chen, C., & Yeh, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01789-5 · Cited by 26
Sanz, R. L., Inserra, F., Menéndez, S. G., Mazzei, L. J., Ferder, L., & Manucha, W. A. (2023) · Current Hypertension Reports · doi:10.1007/s11906-023-01240-w · Cited by 26
Lo, S., Kornelius, E., Liao, P., Huang, J., Yang, Y., & Huang, C. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110685 · Cited by 23
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Connelly, K. A., O’Meara, E., Zieroth, S. R., & Sherifali, D. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02154-w · Cited by 29
Pan, S., Su, E.-L., Huang, C., Chuang, S., Chiang, C., Chen, C., & Cheng, H. (2024) · Age and Ageing · doi:10.1093/ageing/afae175 · Cited by 24
Aguilar-Ballester, M., Hurtado-Genovés, G., Taberner-Cortés, A., Herrero-Cervera, A., Martínez‐Hervás, S., & Navarro, H. G. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22020660 · Cited by 29
Pratley, R. E., Crowley, M. J., Gislum, M., HERTZ, C. L., Jensen, T. B., Khunti, K., Mosenzon, O., & Buse, J. B. (2021) · Diabetes Therapy · doi:10.1007/s13300-020-00994-9 · Cited by 27
Self-citationFauchier, L., Boriani, G., de Groot, J. R., Kreutz, R., Rossing, P., & Camm, A. J. (2021) · EP Europace · doi:10.1093/europace/euab184 · Cited by 22
Management of Heart Failure in a Resource-Limited Setting: Expert Opinion from India
Jain, P., Guha, S., Kumar, S., Sawhney, J. P. S., Sharma, K. H., Sureshkumar, K. P., Mehta, A., Dhediya, R., Gaurav, K., Mittal, R., et al. (2024) · Cardiology and Therapy · doi:10.1007/s40119-024-00367-4 · Cited by 24
“Like-wise, in the VERTIS CV trial involving individuals with type 2 diabetes mellitus (T2DM) and atherosclerotic cardiovascular disease, ertugliflo-zin exhibited noninferiority to the placebo in terms of MACE [37].”
MethodEffects of SGLT2 inhibitors on cardiovascular and renal outcomes in type 2 diabetes
Qiu, M., Ding, L., & Zhou, H. (2021) · Medicine · doi:10.1097/md.0000000000025121 · Cited by 22
“The 7 trials included in this study consisted of the VERTIS CV trial([5]) assessing ertugliflozin, the SCORED trial([6]) and the SOLOIST-WHF trial([7]) assessing sotagliflozin, the DECLARE–TIMI 58 trial([10]) assessing dapagliflozin, the EMPA-REG OUTCOME trial([11]) assessing empagliflozin, and the CREDENCE trial,([12…”
MethodChang, T., Lu, C.-T., Huang, H.-L., Chou, R., Chang, C., Liu, C.-T., Huang, P., & Lin, S. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.882181 · Cited by 23
Ejiri, K., Miyoshi, T., Kihara, H., Hata, Y., Nagano, T., Takaishi, A., Toda, H., Namba, S., Nakamura, Y., Akagi, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-19371-6 · Cited by 23
“Under the following circumstances, the investigators evaluated the data and patients’ vital signs: (1) discontinuation of study treatment; (2) dose increase of specific treatment for heart failure; (3) initiation of a new treatment for heart failure; and (4) withdrawal from the study.”
Richardson, T. L., Halvorson, A. E., Hackstadt, A. J., Hung, A. M., Greevy, R. A., Grijalva, C. G., Elasy, T. A., & Roumie, C. L. (2023) · Annals of Internal Medicine · doi:10.7326/m22-2751 · Cited by 24
Liu, Y., An, C., Liu, P., Yang, F., & Zhao, Q. (2023) · Renal Failure · doi:10.1080/0886022x.2023.2217287 · Cited by 27
Salmen, T., Șerbănoiu, L. I., Bica, I.-C., Serafinceanu, C., Muzurović, E. M., Janež, A., Busnatu, Ș., Banach, M., Rizvi, A. A., Rizzo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24119760 · Cited by 24
McCoy, R. G., SWARNA, K. S., Deng, Y., Herrin, J. S., Ross, J. S., Kent, D. M., Borah, B. J., Crown, W. H., Montori, V. M., Umpierrez, G. E., et al. (2024) · JACC Advances · doi:10.1016/j.jacadv.2024.100852 · Cited by 24
Mechanisms and Perspectives of Sodium-Glucose Co-transporter 2 Inhibitors in Heart Failure
Zeng, Q., Zhou, Q., Liu, W., Wang, Y., Xu, X., & Xu, D. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.636152 · Cited by 26
“The results are summarized in Table 2 (17, 19, 21, 141).”
BackgroundBrata, R. D., Paşcalău, A. V., Frățilă, O., Paul, I. L., Muresan, M. M., Cămărășan, A., & Ilias, T. I. (2024) · Healthcare · doi:10.3390/healthcare12232464 · Cited by 21
“This restriction is consistent with the lack of a direct demonstration of the SGLT2 transporter’s expression in endothelial cells or blood vessels [47].”
Goje, I.-D., Barbulescu, G. I., Ordodi, V. L., Ciobotaru, V. G., Ivan, V. S., Buzaș, R., Tunea, O., Bojin, F. M., & Lighezan, D.-F. (2025) · Pharmaceuticals · doi:10.3390/ph18050681 · Cited by 28
“…Cardiovascular Outcomes in Patients with Diabetic Nephropathy) [123], VERTIS CV (Cardiovascular Outcomes with Empagliflozin in Patients with T2DM) [124], EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome events trial in T2DM) [125], and DECLARE-TIMI 58 (Dapagliflozin and Cardiovascular…”
Aristizábal-Colorado, D., Corredor-Rengifo, D., Sierra-Castillo, S., López-Corredor, C., Trujillo, D. A. V., Weir-Restrepo, D., Izquierdo‐Condoy, J. S., Ortiz‐Prado, E., Rico-Fontalvo, J. E., Gomez‐Mesa, J., et al. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1605746 · Cited by 37
Cardiorenal Protection in Diabetic Kidney Disease
Lee, J. F., Berzan, E., Sridhar, V. S., Odutayo, A., & Cherney, D. Z. I. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2021.987 · Cited by 23
“SGLT2 inhibitors have established benefits on kidney, CV and HF outcomes in the setting of DKD. GLP-1 RA therapies have also been noted to have heart and kidney protective effects, although benefits in the kidney at this time appear to be isolated to preventing the progression of proteinuria, and CV benefits appear to…”
BackgroundInfluentialSelf-citationYin, D., Qiu, M., & Duan, X.-Y. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.724405 · Cited by 21
“the data from the two trials of VERTIS CV (Cannon et al., 2020) and EMPEROR-Reduced (Packer et al.”
BackgroundMethodGouda, P., Zheng, S., Peters, T. M., Fudim, M., Randhawa, V. K., Ezekowitz, J. A., Mavrakanas, T. A., Giannetti, N., Tsoukas, M. A., Lópes, R. D., et al. (2021) · Current Heart Failure Reports · doi:10.1007/s11897-021-00527-w · Cited by 28
Kushner, P. R., Cavender, M. A., & Mende, C. W. (2022) · Clinical Diabetes · doi:10.2337/cd21-0119 · Cited by 29
“VERTIS CV (N = 8,238) (44) Patients aged $40 years with type 2 diabetes and established ASCVD MACE (composite of death from CV causes, nonfatal MI, or nonfatal stroke) 0.”
Ali, M. U., Mancini, G. B. J., Fitzpatrick‐Lewis, D., Lewis, R., Jovkovic, M., Zieroth, S. R., O’Meara, E., Connelly, K. A., & Sherifali, D. (2022) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2022.05.011 · Cited by 26
Treewaree, S., Kulthamrongsri, N., Owattanapanich, W., & Krittayaphong, R. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1046194 · Cited by 24
Recent advances in the treatment of patients with obesity and chronic kidney disease
Wahab, R. A., COHEN, R. V., & le Roux, C. W. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2203517 · Cited by 25
Monnerat, S., Refardt, J. C., Potasso, L., Meier, C., & Christ‐Crain, M. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad238 · Cited by 21
Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Conde, A. C., Martín, D. M., Ruíz, R. C., Olmo, M. R. F., Ariño, C. M., Gómez‐Doblas, J. J., Górriz, J. L., Mazón‐Ramos, P., García–Moll, X., Soler, M. J., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12123925 · Cited by 23
“Canagliflozin Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) [77] Seconda y endpoint Secondary endpoin ‡”
BackgroundMethodInfluentialBaseline Characteristics of Patients Enrolled in the EMPACT-MI Trial
Harrington, J., Udell, J. A., Jones, W. S., Anker, S. D., Bhatt, D. L., Petrie, M. C., Andersen, K. R., Sumin, M., Zwiener, I., Hernandez, A. F., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2990 · Cited by 21
Emerging role of antidiabetic drugs in cardiorenal protection
Fu, W.-J., Huo, J., Mao, Z., Pan, S.-K., Liu, D., Liu, Z., Wu, P., & Gao, Z. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1349069 · Cited by 24
Rodriguez‐Valadez, J. M., Tahsin, M., Masharani, U. B., Park, M., Hunink, M. G. M., Yeboah, J., Li, L., Weber, E. S., Berkalieva, A., Avezaat, L., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032463 · Cited by 22
“Hematocrit was assessed longitudinally in 8 SGLT2i trials, 16,41,42,44,47–50, 52, 54– 59 , 71 and its baseline values values The majority of longitudinal difference measures (N=51 out of 110 trials risk factors) could be obtained at 50 to 52 weeks of follow-up.”
MethodSingh, A. K., & Singh, R. (2021) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2021.01.006 · Cited by 23
Diabetes Management in Patients with Heart Failure
Shen, J., & Greenberg, B. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0296 · Cited by 24
Sodium–glucose cotransporter 2 inhibitors: renal outcomes according to baseline albuminuria
Delanaye, P., Wissing, K. M., & Scheen, A. J. (2021) · Clinical Kidney Journal · doi:10.1093/ckj/sfab096 · Cited by 24
“Post hoc analyses focusing on albuminuria and renal outcomes of four cardiovascular outcome trials [EMPA-REG OUTCOME (Empagliflozin Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients), CANVAS (Canagliflozin Cardiovascular Assessment Study), DECLARE-TIMI 58 (Multicenter Trial to Evaluate the Effect…”
InfluentialDisturbed Glucose Metabolism and Left Ventricular Geometry in the General Population
Schmitt, V. H., Billaudelle, A.-M., Schulz, A., Keller, K., Hahad, O., Tröbs, S., Koeck, T., Michal, M., Schuster, A. K.-G., Toenges, G., et al. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10173851 · Cited by 24
“Individuals with T2DM are at a higher risk for developing coronary heart disease [1], heart failure [2], peripheral artery disease [3], and acute cardiovascular events such as myocardial infarction and stroke [4].”
BackgroundLi, Y., & Xu, G. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.106049 · Cited by 21
Sodium-Glucose Cotransporter 2 Inhibitors and Heart Failure: A Bedside-to-Bench Journey
Cappetta, D., Angelis, A. D., Bellocchio, G., Telesca, M., Cianflone, E., Torella, D., Rossi, F., Urbanek, K., & Berrino, L. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.810791 · Cited by 23
“primary and secondary outcomes did not reach a statistical significance (13).”
BackgroundBaker, H. E., Tune, J. D., Mather, K. J., Blaettner, B. S., Clark, H. E., Li, F., Li, X., Kowala, M. C., Fliegel, L., & Goodwill, A. G. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.054 · Cited by 25
Reyes-Farias, C. I., Reategui-Diaz, M., Romani-Romani, F., & Prokop, L. (2023) · PLOS ONE · doi:10.1371/journal.pone.0295059 · Cited by 20
Scheen, A. J. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101594 · Cited by 24
CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes
Schnell, O., Almandoz, J. P., Anderson, L., Barnard-Kelly, K. D., Battelino, T., Blüher, M., Busetto, L., Catrinou, D., Ceriello, A., Cos, X., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02700-0 · Cited by 23
Steven, S., Kuntić, M., Münzel, T. F., & Daiber, A. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100082 · Cited by 26
Metra, M., Tomasoni, D., Adamo, M., Amir, O., Anker, S. D., Bayés‐Genís, A., Böehm, M., Butler, J., Chioncel, O. D., Filippatos, G. S., et al. (2025) · ESC Heart Failure · doi:10.1002/ehf2.15408 · Cited by 28
Bocchi, E. A., Biolo, A., Moura, L. Z., de Figueiredo, J. A., Montenegro, C. E. L., & de Albuquerque, D. C. (2021) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20210031 · Cited by 39
Skeik, N., Elejla, S. A., Sethi, A., Manunga, J. M., & Mirza, A. K. (2023) · Vascular Medicine · doi:10.1177/1358863x221143811 · Cited by 22
Ngoc, N. B., Nguyen, L., Mital, S., Bugden, S., & Nguyen, H. V. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15009 · Cited by 24
SGLT2 Inhibitors: The Next Blockbuster Multifaceted Drug?
Chan, J. C. H., & Chan, M. C. Y. (2023) · Medicina · doi:10.3390/medicina59020388 · Cited by 28
“VERTIS CV [12] (ertugliflozin 5 or 15 mg) MACE 0.”
BackgroundForesta, A., Succurro, E., Baviera, M., Macaluso, G., Fernandez, M. L. O., Roncaglioni, M. C., Fortino, I., Nobili, A., & Sesti, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110742 · Cited by 20
Bai, Y., Jin, J., Zhou, W., Zhang, S., & Xu, J. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.02.006 · Cited by 22
Contemporary Pillars of Heart Failure with Reduced Ejection Fraction Medical Therapy
Rahamim, E., Nachman, D., Yagel, O., Yarkoni, M., Elbaz‐Greener, G., Amir, O., & Asleh, R. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194409 · Cited by 24
Qiu, M., Zhao, L., & Zhan, Z. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.743807 · Cited by 21
“(1) were CREDENCE trial (2), CANVAS Program trial (3), DECLARE-TIMI 58 trial (4), EMPA-REG OUTCOME trial (5), VERTIS CV trial (6), EMPEROR-Reduced trial (7), DAPA-HF trial (8), DAPA-CKD trial (9), SOLOIST-WHF trial (10), and SCORED trial (11).”
BackgroundTargeting NF-κB in diabetic nephropathy: exploring the therapeutic potential of phytoconstituents
Abhirami, B. L., Krishna, A. A., Kumaran, A., & Chiu, C. (2025) · Archives of Pharmacal Research · doi:10.1007/s12272-025-01555-z · Cited by 22
Managing the side effects of sodium-glucose cotransporter-2 inhibitors
Kodur, N., Sharew, B., Lansang, M. C., & Tang, W. H. W. (2025) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.92a.24071 · Cited by 22
Martínez‐Vizcaíno, V., Díez‐Fernández, A., Álvarez‐Bueno, C., Alfonso, J. M., & Cavero‐Redondo, I. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10122713 · Cited by 21
“Our study, including data from a recently published RCT assessing the effect of ertugliflozin on cardiovascular and renal outcomes in patients with T2DM and established atherosclerotic CVD [33], not only compares the four marketed SGLT2i in the US and the”
MethodSGLT2 inhibitors in heart failure with reduced ejection fraction
Das, U. S., Paul, A., & Banerjee, S. (2021) · The Egyptian Heart Journal · doi:10.1186/s43044-021-00218-w · Cited by 22
“Similarly, canagliflozin in the CANVAS trial [13] showed a lower risk of cardiovascular events than those who received the placebo, and Ertugliflozin in the VERTIS-CV trial [14] was non-inferior to placebo with respect to major adverse cardiovascular events.”
BackgroundMechanisms of current therapeutic strategies for heart failure: more questions than answers?
Khan, M. S., Shahid, I., Greene, S. J., Mentz, R. J., DeVore, A. D., & Butler, J. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvac187 · Cited by 22
Fatima, K., Suri, A., Rija, A., Kalim, S., Javaid, S., Arif, Z., Abedin, M. F. E., Raza, Y., Kalim, N., Azam, F., et al. (2022) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2022.101582 · Cited by 19
The Impact of SGLT2 Inhibitors in the Heart and Kidneys Regardless of Diabetes Status
Matthews, J. R., Herat, L. Y., Schlaich, M. P., & Matthews, V. B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814243 · Cited by 26
“Of significance, the EMPA-REG [51], VERTIS-CV [53] and the CREDENCE [52] clinical trials have all confirmed that the dip in eGFR is not associated with progressive loss of long-term kidney function or acute kidney injury [79].”
InfluentialJeon, J. Y., & Kim, D. J. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0317 · Cited by 26
Exploring the Cardiorenal Benefits of SGLT2i: A Comprehensive Review
Cersosimo, A., Drera, A., Adamo, M., Metra, M., & Vizzardi, E. (2024) · Kidney and Dialysis · doi:10.3390/kidneydial4040016 · Cited by 24
Griffin, K. E., Snyder, K., Javid, A. H., Hackstadt, A. J., Greevy, R. A., Grijalva, C. G., & Roumie, C. L. (2024) · Diabetes Care · doi:10.2337/dc24-1546 · Cited by 21
Arshad, A., Sarween, N., & Sharif, A. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.06.029 · Cited by 20
Beneficial Effect of Sodium-Glucose Co-transporter 2 Inhibitors on Left Ventricular Function
Shi, F., Li, H., Shen, L., Xu, L., Ge, H., Gu, Z., Lin, H., & Pu, J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab834 · Cited by 24
Wang, A., Li, Z., Zhuo, S., Gao, F., Zhang, H., Zhang, Z., Ren, G., & Ma, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.857952 · Cited by 23
“Ertugliflozin VERTIS-CV (26) 8,246 T2DM patients with ASCVD and eGFR≥30 mL/min/1.”
BackgroundInfluentialDapagliflozin for the treatment of chronic kidney disease
Kurata, Y., & Nangaku, M. (2022) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2099373 · Cited by 21
Li, J., Cheng, J., Zhang, W., Lan, L., & Ge, W. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2022.108362 · Cited by 24
Zhao, L.-M., Zhan, Z.-L., Ning, J., & Qiu, M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.751496 · Cited by 18
“Included eight trials were all with low risk of bias (Supplementary Figure S1) and consisted of one trial (Zinman et al., 2015; Bakris et al., 2020; Filippatos et al., 2021) of finerenone (i.e., FIDELIO-DKD) and seven trials (Wanner et al., 2016; Neal et al., 2017; Neuen et al., 2018; Wanner et al., 2018; Mahaffey et…”
BackgroundInfluentialButler, J., Anker, S. D., Filippatos, G., Usman, M. S., Ferreira, J. P., Zannad, F., & Packer, M. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab704 · Cited by 18
Nyström, T. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15696 · Cited by 21
“95 101 There is still some debate regarding the risk of fractures and amputation, which was shown in one RCT, 25 but not reported in other RCTs 24,26,45 ; the CANVAS trial 25 noted a higher occurrence of ampu-tations with canagliflozin, attributed to its disproportionate exposure in the database,…”
Pham, L. T. T., Mangmool, S., & Parichatikanond, W. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00240 · Cited by 19
Guidelines for treating heart failure
Kittleson, M. M. (2024) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2024.10.002 · Cited by 19
Diabetes and cardiovascular disease in older adults
Bilal, A., & Pratley, R. E. (2024) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.15259 · Cited by 21
Self-citationSGLT2 inhibitors and acute kidney injury
Nakao, Y., Mori, M., Mori, Y., & Bonventre, J. V. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf132 · Cited by 21
Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure: An Updated Meta-Analysis
Cao, Y., Li, P., Li, Y., & Han, Y. (2022) · ESC Heart Failure · doi:10.1002/ehf2.13905 · Cited by 19
Jabbour, S. A., Ibrahim, N. E., & Argyropoulos, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11206051 · Cited by 20
“On the basis of data from the EMPA-REG OUTCOME [11], DAPA-CKD [21], VERTIS CV [8], and CREDENCE [22] trials, as well as real-world evidence [46], increased frequency in monitoring, beyond that indicated by a patient’s diabetes and kidney disease, is not warranted unless there are signs and symptoms of volume depletion…”
BackgroundMethodChen, G., Shen, S., Zhang, K., Zhou, L., Shen, J., Zhao, J., Ding, S.-G., Ma, L., & Gao, H. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.926979 · Cited by 18
“Secondary prevention of atherosclerotic cardiovascular disease Four RCTs enrolled 22218 subjects and reported the cardiovascular outcomes of applying SGLT2 inhibitors to patients with ACD (18, 22, 25, 26).”
BackgroundCardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients
Chen, X., Wang, J., Lin, Y., Yao, K., Xie, Y., & Zhou, T. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1236404 · Cited by 21
Kongmalai, T., Hadnorntun, P., Leelahavarong, P., Kongmalai, P., Srinonprasert, V., Chirakarnjanakorn, S., Chaikledkaew, U., McKay, G. J., Attia, J. R., & Thakkinstian, A. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1216160 · Cited by 23
Zhang, T., Gao, X., Chen, T., Zhang, H., Zhang, X., Xin, Y., Shi, D., Du, Y., Xu, L., & Zhou, Y. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02368-y · Cited by 19
“The cardio-vascular benefits of SGLT2i have been examined in six cardiovascular outcome trials (CVOTs) among T2DM patients [7–12].”
Tang, H., Zhang, B., Lu, Y., Donahoo, W. T., Ospina, N. S., Kotecha, P., Lu, Y., Tong, J., Smith, S. M., Rosenberg, E. I., et al. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16147 · Cited by 20
SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy
Viggiano, D., Joshi, R., Borriello, G., Cacciola, G., Gonnella, A., Gigliotti, A., Nigro, M., & Gigliotti, G. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041241 · Cited by 21
“Therefore, SGLT2i reduce kidney glucose reabsorption, thereby lowering blood glucose levels and exerting beneficial effects on renal and cardiovascular outcomes in T2DM [9].”
Lalagkas, P. N., Poulentzas, G., Kontogiorgis, C. A., & Douros, A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1921735 · Cited by 19
The impact of diabetes on heart failure development: The cardio-renal-metabolic connection
Valensi, P. E., Prévost, G., Pinto, S., Halimi, J., & Donal, E. (2021) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2021.108831 · Cited by 20
Alkabbani, W., & Gamble, J. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s281602 · Cited by 19
Heart Failure in Type 1 Diabetes: A Complication of Concern? A Narrative Review
Gómez‐Pérez, A. M., Damas-Fuentes, M., Cornejo-Pareja, I. M., & Tinahones, F. J. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10194497 · Cited by 20
Scheen, A. J., & Delanaye, P. (2021) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2022.2014322 · Cited by 21
“Four placebo-controlled randomized clinical trials (RCTs) analyzed the effects of different SGLT2is on a composite CV outcome (major CV events or MACE-3 points: CV mortality, first nonfatal myocardial infarction, first nonfatal stroke) as primary endpoint in patients with T2D and high CV risk: EMPA-REG CONTACT André J…”
MethodGiaccari, A., Pontremoli, R., & Filardi, P. P. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.12.050 · Cited by 38
Kidney function assessment and endpoint ascertainment in clinical trials
Khan, M. S., Bakris, G. L., Packer, M., Shahid, I., Anker, S. D., Fonarow, G. C., Wanner, C., Weir, M. R., Zannad, F. M., & Butler, J. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab832 · Cited by 19
Metadata
- Authors
- Cannon, C. P., Pratley, R., Dagogo-Jack, S., Mancuso, J., Huyck, S., Masiukiewicz, U., Charbonnel, B., Frederich, R., Gallo, S., Cosentino, F., Shih, W. J., Gantz, I., Terra, S. G., Cherney, D. Z. I., & McGuire, D. K.
- Affiliations
- Rutgers, The State University of New Jersey (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2020-10-08
- Volume
- 383
- Issue
- 15
- Pages
- 1425-1435
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W3089283105
- Cited by
- 1,514
- References
- 14
- Citations by year
- 2026: 126 · 2025: 177 · 2024: 231 · 2023: 269 · 2022: 298 · 2021: 364 · 2020: 47
- FWCI
- 184.60
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Funders
- Pfizer
- Merck
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- ertugliflozin, SGLT2 inhibitors, type 2 diabetes, atherosclerotic cardiovascular disease, major adverse cardiovascular events, heart failure hospitalization, cardiovascular mortality, non-inferiority, renal safety, non-inferiority margin, myocardial infarction, stroke, renal replacement therapy, serum creatinine doubling, cardiovascular risk stratification
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Aged, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Diabetic Nephropathies, Double-Blind Method, Female, Hospitalization, Humans, Male, Middle Aged, Placebos, Bridged Bicyclo Compounds, Heterocyclic, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.